spacer
home > > winter 2019 > exploring growth strategies for smaller cros
PUBLICATIONS


Exploring Growth Strategies for Smaller CROs

Over the last several decades, clinical trials have increased in size, cost, complexity, and duration, resulting in sponsors becoming increasingly reliant on the outsourcing services of CROs. The number of countries involved in Phase 3 clinical studies doubled between 2005-15, and the number of investigative sites increased by 63%. Simultaneously, the mean number of patients declined by 18%, adding complexity to the study start-up process and putting greater pressure on CROs to deliver (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Zac Beda is Director and co-founder at Upsilon Global. As Director of Europe and APAC, he is responsible for supporting business development and bid-defence activities for their small/ mid-sized CRO partners, helping them to win more clinical studies, upscale their operations, and cost-effectively launch clinical programmes in new countries and new regions. Their model is built on a global network of clinical, regulatory, and quality affairs consultants, built over three decades of experience within the healthcare industry. Upsilon Global are currently operational in over 50 countries across six continents.
spacer
Zac Beda
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals welcomes Keensight Capital as majority shareholder


More info >>

White Papers

The Impact of Components on Drug Quality and Risk Mitigation

West Pharmaceutical Services, Inc.

Expectations for quality by regulatory agencies are increasing at a very fast pace, especially for prefilled drug delivery formats, thanks to increased focus on reducing risk to patient safety. The trend has resulted in delays for new drug applications, more recalls of marketed products and even drug shortages if the container system and drug contents are suspect for quality issues. The pharmaceutical market is now requiring manufacturers of containers and components to meet new expectations with a quality culture and very high product reliability. The need to bridge the gap and provide superior quality products has been a driver for manufacturing technology investments, more robust control strategies and the introduction of next generation elastomer components.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement